Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care

Kathleen Wiley RN, MSN, AOCNS®
Voice

Description

As researchers learn more about how combination therapy combats drug resistance and lessens the changes of tumor evasion of the immune system, immune checkpoint inhibitors are receiving approval for a broader range of indications. However, recent U.S. Food and Drug Administration (FDA) approvals have centered around hematologic malignancies and the emergence of two new biosimilars.

View Article @ voice.ons.org

ONS Voice Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Voice Articles

Related Topics